5 research outputs found

    Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications

    Get PDF
    There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologies have the potential to achieve retention of the dosage form in the upper gastrointestinal tract (GIT) that can be sufficient to ensure complete solubilisation of the drugs in the stomach fluids, followed by subsequent absorption in the stomach or proximal small intestine. This can be beneficial for drugs that have an “absorption window” or are absorbed to a different extent in various segments of the GIT. Therefore, gastroretentive technologies in tandem with controlled-release strategies could enhance both the therapeutic efficacy of many drugs and improve patient compliance through a reduction in dosing frequency. The paper reviews different gastroretentive drug delivery technologies and controlled-release strategies that can be combined and summarises examples of formulations currently in clinical development and commercially available gastroretentive controlled-release products. The different parameters that need to be considered and monitored during formulation development for these pharmaceutical applications are highlighted

    Gastroretentive Floating Matrix Tablets of Atazanavir Sulphate Using Low Density Polymers.

    Get PDF
    The study was aimed at formulation and evaluation of Fast Disintegrating Tablets (FDTs). Using a taste masking polymer Eudragit E100, to mask the taste of a delivered drug i.e., Quetiapine Fumarate (QTF). Taste masking was done by solvent evaporation technique in absolute Ethanol as solvent system. Fast Disintegrating Tablets of QTF were prepared by using different echniques like Superdisintegrants addition method (Croscarmellose sodium (CCS), Sodium starch glycolate (SSG) and crospovidone (CP)), sublimation method (Camphor) and Effervescent formulation approach (sodiumbicarbonate+citrcacid). All the formulations were evaluated for flow properties, hardness, friability, content uniformity, wetting time, in vivo disintegration time (DT), release profiles. All the formulations showed satisfactory mechanical strength and other formulation parameters within the range. Dissolution parameters such as, Initial Dissolution Rate (IDR), Dissolution Efficiency (DE), Mean Dissolution Time (MDT) and Relative Dissolution Rate (RDR) were calculated. The optimized formula D5 prepared by using 10 % CP as a superdisintegrant and 12 % Camphor as subliming agent, which showed shortest DT (17 Sec) ( Q10= 88%, WT= 37Sec). The drug polymer complex was subjected to FTIR studies to understand the degree of interaction between drug and polymer. The dissolution parameters such as IDR, DE, RDR for the optimized formulation exhibited 1.8 fold increase when compared to marketed product. It can be concluded that the orally fast disintegrating tablets of QTF with better biopharmaceutical properties than conventional marketed tablet obtained using formula D5

    Nanovectors for targeted chemotherapy in cervical cancer

    Get PDF
    A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, in fulfilment of the requirements for the degree of Master of PharmacyCervical Intraepithelial Neoplasia (CIN) or Human Papilloma Virus (HPV) is known as the precancerous stages of cervical cancer and may be treated with antineoplastic agents Current treatment includes intravenous administration of Gemcitabine and 5-Fluorouracil however, these drugs have an undesirable side effect profile. This may be overcome by local administration of chemotherapeutic drugs to the site of the cancer. The purpose of this study was to design a drug delivery system that can be locally administered to the site of the cervical cancer and possess thermosonic properties. Designs of three Thermosonic Injectable Organogels (TIO’s) were undertaken using ring opening polymerization (open ring reaction) to formulate three different gels to test the response ability of the gels against thermal and ultrasound exposure. The times taken for these gels to form were recorded at below 15 minutes. All three TIO’s responded differently to thermal and ultrasound stimuli. Physical changes in the gels were noted and further studies were undertaken to confirm their responsiveness towards the dual-stimuli. All three TIO’s showed a dense microstructure containing pores catering for the incorporation of drugs or drug-loaded carriers. Rheological studies showed that there was an increase in viscosity of the gels under increasing heat even though the response differed between TIO formulations. The gels were non-cytotoxic at distinct concentrations ranging between 6.1mg/ml-7.8mg/ml. Solid Lipid Nanospheres (SLN’s) were then designed which encapsulated the mode antineoplastic drug 5-Fluorouracil. The SLN’s were spherical in shape and had an acceptable poly dispersion index (PDI) which was below 0.7 after ultrasonication and filtration of prepared samples. The SLN’s were then incorporated by direct additition and dispersion into the TIO formulations before undertaking the open ring reaction to form Thermosonic Injectable Nano-Organogels (TINO’s). The TINO’s were analysed for its swelling and erosive properties. Results showed that the TINO’s posesses both swelling and erosive properties. Furthermore, the TINO’s underwent dissolution studies that involved thermal and thermal with ultrasound stimuli to test the drug release rate and the stimuli responsiveness of the TINO. Results of the SLN’s showed a very slow release rate whether exposed to a single (thermal) or both thermal and ultrasound stimuli, indicating that the addition of ultrasound stimuli did not alter the drug release from the SLN’s. However, the incorporation of the SLN’s into the TIO’s prolonged the release rate. Hence increasing the SLN concentration in the TIO’s reduced the response towards ultrasound stimuli. Therefore lower ratios of SLN:TIO provided superior responsiveness compared to higher concentrations of SLN:TIO. TIO 1 and TINO 2 released drug with thermal stimuli and higher drug release occurred with exposure to both thermal and ultrasound stimuli. These TINO’s in conjunction with ultrasound responsiveness may be used as a potential platform for the delivery of antineoplastics in treating cervical cancer.MT201

    In-vivo Study of Quetiapine Fumarate Superporous Hydrogels

    Full text link
    This study aims to design and evaluate a gastroretentive drug delivery system using second generation Superporous hydrogels using Factorial design approach. Optimized formulation was assessed for pharmacokinetic parameters by In-vivo study. Pharmacokinetic analysis of Quetiapine Fumarate plasma concentration–time data provided the following pharmacokinetic parameters like Cmax values ranging (690.58 ± 1.1 ng/mL to 524.37 ± 1.6 ng/mL), Tmax values ranging (1.5 ± 0.0 to 6.0 ± 0.0 Hours), AUC values ranging (5345.67 ± 11.34 h.ng/mL to 5345.67 ± 4.59 h.ng/mL). Results obtained for the formulated product prepared with superporous hydrogel technology shows prolonged release while maintaining Q Value with reduce plasma drug fluctuations in comparison to the Pure drug

    In-vivo study of quetiapine fumarate superporous hydrogels

    No full text
    This study aims to design and evaluate a gastroretentive drug delivery system using second generation Superporous hydrogels using Factorial design approach. Optimized formulation was assessed for pharmacokinetic parameters by In-vivo study. Pharmacokinetic analysis of Quetiapine Fumarate plasma concentration–time data provided the following pharmacokinetic parameters like Cmax values ranging (690.58 ± 1.1 ng/mL to 524.37 ± 1.6 ng/mL), Tmax values ranging (1.5 ± 0.0 to 6.0 ± 0.0 Hours), AUC values ranging (5345.67 ± 11.34 h.ng/mL to 5345.67 ± 4.59 h.ng/mL). Results obtained for the formulated product prepared with superporous hydrogel technology shows prolonged release while maintaining Q Value with reduce plasma drug fluctuations in comparison to the Pure drug
    corecore